NeoGenomics (Nasdaq: NEO) JP Morgan Healthcare Conference Investor Presentation January 2026 Mission We save lives by improving patient care. Vision We are becoming the world's leading provider of comprehensive cancer testing, data and solutions through uncompromising quality, exceptional customer experience, and innovative products and services. Safe Harbor Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company"). Statements contained herein ar ...

Core Viewpoint - NeoGenomics, Inc. has successfully resolved its litigation with Natera, as Natera voluntarily dismissed its appeal, leaving the North Carolina District Court's ruling in favor of NeoGenomics intact [1][2]. Legal Outcome - The North Carolina District Court granted NeoGenomics' motion for summary judgment, ruling that Natera's patent claims are invalid due to ineligible subject matter. The court dismissed Natera's claims against NeoGenomics with prejudice and issued a declaratory judgment of invalidity for both asserted patents [2]. Company Focus - Following the dismissal of the litigation, NeoGenomics plans to concentrate on the clinical launch of its RaDaR ST molecular residual disease assay, scheduled for the first quarter of 2026 [3]. Company Overview - NeoGenomics, Inc. is a leading cancer diagnostics company specializing in cancer genetics testing and information services. The company offers a comprehensive range of oncology-focused testing services to oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms [3]. - The company is headquartered in Fort Myers, Florida, and operates a network of CAP-accredited and CLIA-certified laboratories across the United States, as well as a CAP-accredited laboratory in Cambridge, United Kingdom [3].

Summary of NeoGenomics FY Conference Call (December 02, 2025) Company Overview - **Company**: NeoGenomics (NasdaqCM:NEO) - **Industry**: Life Science Tools and Diagnostics Key Points Clinical Business Performance - Clinical volume increased by approximately **15%** and revenues rose by about **18%** [2][3] - Excluding Pathline, total revenue growth was around **12%** [2] - Five highlighted products now account for **24%** of clinical revenue, with NGS contributing to about **33%** of total clinical revenue [3] Sales Force and Market Penetration - Investments in the sales force are yielding positive results, enhancing productivity and customer experience [2][4] - Focus on therapy selection and MRD (Minimal Residual Disease) market penetration is a strategic priority [2][3] NGS (Next-Generation Sequencing) Business - NGS growth is above market rates, with NeoGenomics achieving **24%** growth in this segment [6] - The company anticipates continued above-market growth due to new product launches, including the PanTracer family and LBX [6][7] - The Pathline acquisition is expected to solidify the company's presence in the Northeast market, which is currently under-penetrated [7] Future Growth Drivers - Anticipated product launches in **2026** include RaDaR ST with initial indications for head and neck and breast cancers [19][51] - Additional indications for RaDaR ST are expected to be available in late **2026** [51] - Liquid biopsy and enhancements to the PanTracer portfolio are also seen as significant growth opportunities [20][24] Biopharma Business Challenges - The biopharma segment has faced erosion, representing about **6%** of total revenue [31][36] - Modest erosion is expected to continue into **2026**, with a return to growth anticipated in **2027** [31] - New offerings like RaDaR ST and Trapelo are expected to improve competitiveness in the biopharma space [32] Market Positioning and Share Gains - NeoGenomics is experiencing share gains across various modalities, with NGS and therapy selection being key areas of growth [40][44] - The company aims to balance high-volume contracts with more valuable contracts to enhance average unit price (AUP) [44] Operational Efficiency and Technology Investments - The company is investing in digital pathology and AI to improve operational efficiency and gross margins [78][82] - Transitioning to the NovaSeq X platform is expected to enhance gross margin improvements starting in **2026** [81] Reimbursement and Market Strategy - RaDaR ST has secured reimbursement for its initial indications, with rates around **$3,900** for initial setups and **$1,158** for subsequent time points [58] - The company is targeting specific physician groups for its MRD solutions, particularly in under-penetrated markets [57] Upcoming Catalysts - Key studies and data readouts are expected at major conferences, including ASH and San Antonio Breast, which could impact the market trajectory for MRD and liquid biopsy [64][65] Conclusion - NeoGenomics is positioned for growth in the clinical diagnostics space, with strategic investments in sales, product development, and operational efficiency. The company is optimistic about future performance despite challenges in the biopharma segment.

Core Insights - NeoGenomics will present research at ISLB 2025 demonstrating high concordance between its RaDaR ST and RaDaR 1.0 MRD assays [1] Group 1 - The presentation will include four additional posters alongside the main research findings [1]

Financial Performance - Clinical revenue increased by 18%[17], or 15% excluding Pathline[20] - Clinical volume grew by 15%[19], or 10% excluding Pathline[20] - NGS revenue increased by 24% year-over-year[20] - Adjusted gross profit was $85 million, a 7% increase from the prior year[19, 20] - Adjusted EBITDA was $12 million, representing a 9% decrease[19] Financial Overview (Q3 2025 vs Q3 2024) - Revenue increased by 11.9% to $187.8 million[22] from $167.8 million[22] - Adjusted gross profit increased by 6.6% to $85.4 million[22] from $80.1 million[22] - Adjusted gross margin decreased by 228 bps to 45.5%[22] from 47.8%[22] - Adjusted EBITDA decreased by 8.5% to $12.2 million[22] from $13.4 million[22] - Cash and cash equivalents decreased by 54.7% to $164.1 million[22] from $361.9 million[22] FY 2025 Guidance - Revenue is projected to be between $720 million and $726 million, representing a year-over-year growth of 9% to 10%[21] - Adjusted EBITDA is projected to be between $41 million and $44 million, representing a year-over-year growth of 3% to 10%[21]